- Tecfidera (BIIB) TRx for week ending 08/23: 4,049 versus 3,593 previous.
- In related news, the FDA is investigating a multifocal leukoencephalopathy case in a patient being treated with Novartis' (NVS) MS treatment Gilenya.
- Although NVS says the infection is unlikely to have been caused by the drug, it's worth noting that BIIB's Tysabri increases the risk of the same infection and was briefly withdrawn from the market due to concerns.
- Tecfidera is BIIB's new MS treatment and although some studies have linked an early formulation of the drug to multifocal leukoencephalopathy, a connection between Tecfidera itself and the infection is less clear.
Tefidera sales +13% w/w, FDA probes PML case in Gilenya patient
Sep 3 2013, 07:53 ET